X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (15) 15
humans (15) 15
oncology (13) 13
male (11) 11
middle aged (10) 10
pharmacology & pharmacy (7) 7
adult (6) 6
aged (6) 6
index medicus (6) 6
medicine & public health (6) 6
human necessities (5) 5
hygiene (5) 5
investigating or analysing materials by determining theirchemical or physical properties (5) 5
measuring (5) 5
medical or veterinary science (5) 5
pharmacokinetics (5) 5
physics (5) 5
preparations for medical, dental, or toilet purposes (5) 5
testing (5) 5
care and treatment (4) 4
dose-response relationship, drug (4) 4
melanoma - pathology (4) 4
mitotic rate (4) 4
pharmacology/toxicology (4) 4
prognosis (4) 4
research (4) 4
skin neoplasms - pathology (4) 4
surgery (4) 4
aged, 80 and over (3) 3
cancer (3) 3
cancer research (3) 3
cohort studies (3) 3
complications and side effects (3) 3
cutaneous malignant-melanoma (3) 3
drug interactions (3) 3
expression (3) 3
lymphatic metastasis (3) 3
neoplasms - drug therapy (3) 3
neoplasms - metabolism (3) 3
pazopanib (3) 3
pyrimidines - administration & dosage (3) 3
sentinel lymphadenectomy (3) 3
sulfonamides - administration & dosage (3) 3
thin melanomas (3) 3
treatment outcome (3) 3
trial (3) 3
tumors (3) 3
young adult (3) 3
administration, oral (2) 2
american joint committee (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bevacizumab (2) 2
bioavailability (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - enzymology (2) 2
breast-cancer (2) 2
cell (2) 2
colorectal cancer (2) 2
cytochrome p-450 cyp3a (2) 2
cytochrome p-450 enzyme system - genetics (2) 2
dabrafenib (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease-free survival (2) 2
dosage and administration (2) 2
drug administration schedule (2) 2
drug interaction (2) 2
early-stage melanoma (2) 2
esomeprazole (2) 2
glutathione transferase - genetics (2) 2
imidazoles - administration & dosage (2) 2
imidazoles - pharmacokinetics (2) 2
ketoconazole (2) 2
ketoconazole - pharmacology (2) 2
laser capture microdissection (2) 2
less-than-or-equal-to-1 mm (2) 2
leukemia (2) 2
maximum tolerated dose (2) 2
medical research (2) 2
medicine, experimental (2) 2
melanoma (2) 2
melanoma - classification (2) 2
melanoma - mortality (2) 2
messenger-rna analysis (2) 2
mitosis (2) 2
multivariate analysis (2) 2
neoplasms - pathology (2) 2
oximes - administration & dosage (2) 2
oximes - pharmacokinetics (2) 2
phase-i (2) 2
physiological aspects (2) 2
polymerase chain reaction (2) 2
prognostic factors (2) 2
prognostic-factors (2) 2
prospective studies (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - pharmacokinetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION | Neoplasms - metabolism | Proton Pump Inhibitors - pharmacology | Esomeprazole - administration & dosage | Cytochrome P-450 CYP3A | Ketoconazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Male | Ketoconazole - pharmacology | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inhibitors | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Ketoconazole - adverse effects | Sulfonamides - administration & dosage | Care and treatment | Metabolites | Analysis | Cytochrome P-450 | Tumors | Antiulcer drugs
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2005, Volume 23, Issue 31, pp. 8065 - 8075
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 6/2005, Volume 12, Issue 6, pp. 449 - 458
Lymphatic mapping and sentinel lymphadenectomy (LM/SL) provide important prognostic information for patients with early-stage melanoma. Although the use of... 
Medicine & Public Health | SLN positivity | Sentinel lymphadenectomy | Surgery | Mitotic rate | Tumor-thickness | Oncology | Thin melanomas | Surgical Oncology
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2015, Volume 55, Issue 4, pp. 392 - 400
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2012, Volume 69, Issue 3, pp. 733 - 741
GSK923295 is an inhibitor of CENP-E, a key cellular protein important in the alignment of chromosomes during mitosis. This was a Phase I, open-label,... 
Medicine & Public Health | Cancer Research | Oncology | CENP-E | Pharmacology/Toxicology | Pharmacokinetics | Antimitotic | Cancer | SOLID TUMORS | ONCOLOGY | PHARMACOLOGY & PHARMACY | THERAPIES | PHASE-I | Neoplasms - metabolism | Sarcosine - administration & dosage | Sarcosine - pharmacokinetics | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antimitotic Agents - pharmacokinetics | Chromosomal Proteins, Non-Histone - antagonists & inhibitors | Dose-Response Relationship, Drug | Young Adult | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Adult | Female | Sarcosine - analogs & derivatives | Antimitotic Agents - adverse effects | Drug Administration Schedule | Treatment Outcome | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antimitotic Agents - administration & dosage | Antimitotic Agents - therapeutic use | Neoplasms - drug therapy | Sarcosine - adverse effects | Sarcosine - therapeutic use | Maximum Tolerated Dose | Aged | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Cohort Studies | Complications and side effects | Cellular proteins | Medical research | Care and treatment | Cancer patients | Oncology, Experimental | Diarrhea | Medicine, Experimental | Research | Chromosomes | Tumors | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2013, Volume 71, Issue 1, pp. 93 - 101
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1682 - 1682
Abstract BACKGROUND: Patients with relapsed and/or refractory non-Hodgkin's lymphoma (NHL), especially those with aggressive lymphomas, have overall poor... 
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2013, Volume 31, Issue 5, pp. 1228 - 1235
Background Although combining targeted agents with conventional, first-line cytotoxic therapy has improved survival outcomes in patients with advanced... 
Medicine & Public Health | Dose escalation | Colorectal cancer | Oncology | FOLFOX6 | Pharmacology/Toxicology | CapeOx | Pazopanib | LEUCOVORIN | BEVACIZUMAB | FLUOROURACIL | CAPECITABINE PLUS OXALIPLATIN | COLON-CANCER | TRIAL | ONCOLOGY | RANDOMIZED PHASE-III | FLUOROPYRIMIDINE | IRINOTECAN | PHARMACOLOGY & PHARMACY | 1ST-LINE THERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Fluorouracil - analogs & derivatives | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Treatment Outcome | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Sulfonamides - administration & dosage | Complications and side effects | Dosage and administration | Research | Drug therapy | Studies | Drug dosages | Analysis | Pharmaceutical sciences
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 10/2013, Volume 2, Issue 4, pp. 336 - 341
The aqueous solubility of lapatinib declines significantly at pH >4, suggesting that its bioavailability might be lowered by acid‐reducing drugs. A study was... 
lapatinib | breast cancer | esomeprazole | proton pump inhibitor | drug interaction | Breast cancer | Drug interaction | Lapatinib | Esomeprazole | Proton pump inhibitor | PHARMACOLOGY & PHARMACY
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 3773 - 3773
Journal Article
20.